Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ICU
Upturn stock ratingUpturn stock rating

LMF Acquisition Opportunities Inc (ICU)

Upturn stock ratingUpturn stock rating
$1.83
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/20/2025: ICU (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Outstanding Performance

These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.

Analysis of Past Performance

Type Stock
Historic Profit 18.06%
Avg. Invested days 29
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 5.0
Stock Returns Performance Upturn Returns Performance 2.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/20/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 12.57M USD
Price to earnings Ratio -
1Y Target Price 7
Price to earnings Ratio -
1Y Target Price 7
Volume (30-day avg) 633927
Beta -0.99
52 Weeks Range 1.50 - 27.50
Updated Date 02/21/2025
52 Weeks Range 1.50 - 27.50
Updated Date 02/21/2025
Dividends yield (FY) -
Basic EPS (TTM) -10.19

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -6552.94%

Management Effectiveness

Return on Assets (TTM) -292.92%
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE -
Enterprise Value 15107498
Price to Sales(TTM) 184.88
Enterprise Value 15107498
Price to Sales(TTM) 184.88
Enterprise Value to Revenue 222.17
Enterprise Value to EBITDA -8.13
Shares Outstanding 7183880
Shares Floating 4384909
Shares Outstanding 7183880
Shares Floating 4384909
Percent Insiders 2.55
Percent Institutions 2.52

AI Summary

LMF Acquisition Opportunities Inc. - A Comprehensive Overview

Company Profile:

History and Background:

LMF Acquisition Opportunities Inc. (NASDAQ: LMF) is a special purpose acquisition company (SPAC) formed in February 2021. The company is headquartered in Delaware and led by CEO Michael Feldman. LMF's primary objective is to identify and acquire operating businesses in the consumer, healthcare, and TMT (technology, media, and telecommunications) sectors with substantial growth potential.

Core Business Areas:

LMF primarily focuses on identifying and acquiring businesses with significant potential within its defined sectors. The company leverages its management team's experience and expertise to identify potential targets, conduct due diligence, negotiate terms, and complete acquisitions. Following acquisition, LMF actively works with its portfolio companies to assist with strategic initiatives, operational improvements, and value creation.

Leadership Team and Corporate Structure:

LMF's leadership team comprises experienced professionals with extensive expertise in investment banking, private equity, and relevant industry sectors. Notable individuals include:

  • Michael Feldman, CEO
  • David Yeh, President
  • James H. Evans, Jr., Chairman
  • Joshua Finkelstein, CFO

The company operates with a lean structure, relying on external resources and partnerships for various functionalities.

Top Products and Market Share:

As an SPAC, LMF currently operates as a pre-acquisition entity and does not offer any products or services. Consequently, market share analysis is not applicable at this stage.

Total Addressable Market:

LMF targets acquisitions primarily within the consumer, healthcare, and TMT sectors. These sectors collectively represent a massive global market with significant growth potential. The specific addressable market size will depend on the final target acquired by LMF.

Financial Performance:

Since LMF has not yet completed an acquisition, it does not currently generate revenue or have any established financial metrics. Financial analysis will be relevant once the company acquires and integrates a business.

Dividends and Shareholder Returns:

LMF does not currently distribute dividends as it is in the pre-acquisition phase. Shareholder returns will depend on the performance of the chosen target and the overall success of the acquisition strategy.

Growth Trajectory:

LMF's future growth is directly tied to its acquisition strategy and the performance of the acquired business. The company's long-term potential hinges on identifying a well-positioned target with strong growth potential and effectively integrating it into its operations.

Market Dynamics:

LMF operates within the competitive SPAC market, facing competition from numerous other players targeting various sectors. The market dynamics are characterized by increasing investor scrutiny, evolving regulatory landscape, and the need for careful target selection and execution.

Competitors:

LMF competes with other SPACs in its target sectors, including:

  • Black Spade Acquisition (BPSA)
  • Bridgetown Holdings (BTWN)
  • Social Capital Suvretta Holdings (SUVR)

The competitive landscape will become clearer once LMF identifies a specific target company.

Potential Challenges and Opportunities:

Challenges LMF faces include:

  • Identifying an attractive and suitable target for acquisition.
  • Successfully integrating the acquired business and realizing value creation.
  • Navigating the competitive SPAC landscape and securing investor interest.

Potential opportunities include:

  • Leveraging industry expertise and partnerships to identify high-quality targets.
  • Implementing effective post-acquisition strategies to maximize operational improvements and value creation.
  • Benefiting from favorable market conditions for M&A activity within its focus sectors.

Recent Acquisitions:

LMF has not completed any acquisitions in the past three years as of its formation in 2021.

AI-Based Fundamental Rating:

An AI-based fundamental rating for LMF is currently not available due to the company's pre-acquisition status and lack of established financials. A rating will be possible following the acquisition and integration of a target business.

Sources and Disclaimers:

This overview primarily utilizes information from the following sources:

  • LMF Acquisition Opportunities Inc. website
  • SEC filings
  • Financial news articles
  • Industry reports

Please note that this information is for informational purposes only and should not be considered investment advice. It is imperative to conduct further research and due diligence before making any investment decisions.

This overview offers a comprehensive understanding of LMF Acquisition Opportunities Inc. and its current standing as a SPAC. The company's future trajectory will be determined by its chosen target and the execution of its post-acquisition strategy. While financial and market share analysis is currently limited, ongoing developments and future financial reports will provide further insights into LMF's performance and potential.

About LMF Acquisition Opportunities Inc

Exchange NASDAQ
Headquaters Denver, CO, United States
IPO Launch date 2022-10-28
CEO, President & Executive Director Mr. Eric Schlorff
Sector Healthcare
Industry Biotechnology
Full time employees 12
Full time employees 12

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is headquartered in Denver, Colorado.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​